To identify regulatory events occurring during myogenesis, we characterized the transcriptional regulation of a Drosophila melanogaster actin gene, Actin 57B. Act57B transcription is first detected in visceral muscle precursors and is detectable in all embryonic muscles by the end of embryogenesis. Through deletion analysis we identified a 595 bp promoter element that was sufficient for high levels of expression in all three muscle lineages. This fragment contained a MEF2 binding site conserved between D. melanogaster and Drosophila virilis which bound MEF2 protein in embryo nuclear extracts. Mutation of the MEF2 site severely reduced promoter activity in embryos, and in Mef2 mutants Act57B expression was severely decreased, demonstrating MEF2 is an essential regulator of Act57B. We also showed that MEF2 likely acts synergistically with factors bound to additional sequences within the 595 bp element. These findings underline the importance of MEF2 in controlling differentiation in all muscle lineages. Our experiments reveal a novel regulatory mechanism for a structural gene where high levels of expression in all embryonic muscles is regulated through a single transcription factor binding site. q
Introduction
Studies of muscle development have placed an emphasis on describing the transcription factors that are required for myogenesis. Prominent among these are the members of the myocyte enhancer factor 2 (MEF2) family of transcriptional regulators. The four murine mef2 genes and the single Drosophila Mef2 gene are each expressed in all skeletal, visceral and cardiac lineages during development (Edmondson et al., 1994; Lilly et al., 1994; Nguyen et al., 1994; Taylor et al., 1995; Subramanian and Nadal-Ginard, 1996) , suggesting that they play important roles in the development of the musculature.
In vertebrates the existence of multiple mef2 genes has hindered the characterization of null phenotypes due to overlapping expression patterns and potential functional redundancy of gene products. However, inactivation of the murine mef2c gene resulted in an embryonic lethal phenotype with defects in heart morphogenesis and myogenesis (Lin et al., 1997a) , and abnormal development of smooth muscle cells (Lin et al., 1998) . Drosophila mutants in which all MEF2 function is absent have a failure of muscle differentiation in all muscle lineages, although skeletal, visceral and cardiac myoblasts are still specified (Bour et al., 1995; Lilly et al., 1995) . Together, these results have revealed an evolutionarily conserved central role for MEF2 in the execution of the myogenic program.
Although MEF2 function is required in all muscle lineages, individual muscles can have startlingly different phenotypes. It is therefore thought that MEF2 interacts with tissue specific cofactors to control gene expression in phenotypically different muscles. In support of this is the inability of MEF2 alone to convert fibroblast to myoblasts . Furthermore, MEF2 has been shown to function synergistically with myogenic bHLH proteins to activate the myogenic program in vertebrate skeletal muscles (Kaushal et al., 1994; Molkentin et al., 1995; . MEF2 also functions in collaboration with PAR domain protein-1 in Drosophila skeletal muscles (Lin et al., 1997b) . However, partners for MEF2 to control the differentiation of cardiac and smooth muscle cells have yet to be identified.
Analysis of the cis-regulatory regions of muscle-specific genes has been useful in identifying factors and cofactors required for tissue-specific gene expression. In many cases, genes with broad expression patterns within the musculature have separable enhancer regions which control subsets of the expression pattern of that gene, presumably due to the different arrays of transcription factors present in each muscle type. An extreme example of this is the Mef2 gene in Drosophila in which transcription is controlled by a very large array of upstream enhancers, each of which contribute a subset of the expression of Mef2 during embryogenesis (Lilly et al., 1995; Schulz et al., 1996; Gajewski et al., 1997; Cripps et al., 1998; Cripps et al., 1999; Nguyen and Xu, 1998) .
In this paper we present an example of a gene where high levels of expression in all three embryonic muscle lineages is controlled by MEF2 through a single enhancer binding site. Of the two embryonic muscle actin isoforms, Drosophila Actin 57B is the major myofibrillar actin expressed in skeletal, visceral and cardiac muscle during embryogenesis (Tobin et al., 1990; Keller et al., 1997) . Transcripts of Act57B are first detected at stage 10 in the visceral muscle precursors, with expression in skeletal muscle at stage 11 and by stage 16 this transcript is also found in the dorsal vessel. Using deletion analysis of the upstream promoter sequences, we have identified a minimal 595 bp element that is sufficient for activation in all three muscle lineages. Within the element, a single MEF2 binding site is required for high levels of expression of this promoter in all muscle tissues, suggesting that for Act57B, MEF2 is essential for expression in all embryonic muscles.
Results

Act57B expression pattern
To understand the regulatory events that control Act57B transcription we initially characterized in detail the expression pattern of Act57B during embryogenesis. We used in situ hybridization with a digoxigenin labeled 3 0 UTR antisense probe to visualize the endogenous gene transcripts during embryogenesis. Expression commenced at the germ band extended stage (stage 10) (Fig. 1A) ; at this stage transcripts were detected in the visceral muscle precursors only. By stage 11, Act57B expression was also detected in skeletal myoblasts (Fig. 1B) . As embryogenesis proceeded, Act57B transcripts continued to be expressed in the visceral and somatic muscle lineages (Fig. 1C,D) and by stage 16 were seen in the developing heart (Fig. 1E ). These findings are consistent with those of Tobin et al. (1990) who showed Act57B expression in skeletal and visceral embryonic muscles and Keller et al. (1997) who showed Act57B expression in heart. Our experiments significantly extend previous work by describing in detail the temporal appearance of Act57B transcripts in all muscle lineages at specific stages of embryogenesis.
Structure of the Act57B gene
To localize the transcribed region of Act57B relative to potential regulatory elements we sequenced the entire 5.4 kb EcoRI genomic fragment containing the gene, and mapped onto that the exon structure described by Fyrberg et al. (1981) (Fig. 2A) . To determine the location of the transcription start site, we performed a primer extension assay upon total RNA either from control embryos aged 0-2 h (before Act57B expression), or from embryos aged 15-17 h (after the onset of Act57B expression). The primer was selected such that it would hybridize to Act57B mRNA downstream of the translation start site ( Fig. 2A) . We also performed DNA sequencing reactions upon the 5.4 kb plasmid using Stage 11 embryos with gene activity continuing in visceral muscle precursors and also present in skeletal myoblasts (sm). By stages 15-16 (C,D,I,J), Act57B and reporter gene expression is seen in all skeletal muscles (sk) and the visceral muscles (vi). At stage 16 Act57B expression is detected in the heart (ht) (E,K). All embryos (except E and K) are lateral views oriented with anterior to left and dorsal up. (E) and (K) are dorsal views to show the heart tube with anterior to left. Scale bars represent 100 mm.
the same primer and electrophoresed these reactions alongside the primer extension products. A primer extension product was generated only in the 15-17 h collection lane, and migrated with the thymine at position 101 of the sequencing reaction. These results indicate that transcription starts with an A ribonucleotide 90 bp upstream of the AUG initiation codon. Although it is formally possible that the transcription start site is contained within a more 5 0 exon, this is unlikely since there is a consensus TATA box located 33 bp upstream of the identified start site and the sequence of both the TATA box and start site are strongly conserved in D. virilis (see below).
Regulatory sequences required for Act57B expression
To identify cis-acting DNA sequences controlling transcription of Act57B, we isolated DNA corresponding to upstream sequence proximal to the transcription start site (22479/12) as well as DNA corresponding to the intron (1100/1831). We tested these sequences for enhancer activity in vivo in transgenic animals using a lacZ reporter construct (Fig. 3) . The promoter fragment 22479/12 directed lacZ expression in a pattern that recapitulated the endogenous gene expression with activity seen first in the visceral myoblasts at stage 10 ( Fig. 1G) , followed by activity at stage 11 in the skeletal muscle precursors (Fig. 1H ) and stage 16 in the heart (Fig. 1K ), although staining in the small heart tube was occasionally irregular. The intron sequence contained no regulatory regions which were sufficient for muscle specific expression since there was no bgalactosidase accumulation at any embryonic stage (Figs. 1L and Fig. 3) ; intron sequences may contain regulatory elements that work in concert with upstream elements. These findings demonstrate that all the regulatory sequences for Act57B expression during embryogenesis are contained within the 22479/12 fragment.
In order to localize regulatory elements within the 22479/ 12 promoter element, we tested additional lacZ reporter constructs with serial deletions of the 5 0 end (Fig. 3) . Deletion of sequences between 22479 bp to 2593 bp had no effect on either the timing or levels of lacZ expression, and antibody staining was identical to that shown in Fig. 1 for the 22479/ 12 fragment (Fig. 3) . Importantly, lacZ expression was still detected in all three muscle lineages. Fig. 3 . Identification of a minimal promoter sequence that directs muscle specific lacZ expression. Top: gene structure of Actin 57B showing the transcription start site (arrow), exons (shaded boxes denote the translated sequence) and the intron. Bottom: serial 5 0 end deletions of the promoter sequence were fused to a lacZ reporter and assayed for muscle specific activity using b-galactosidase antibody in whole mount embryos. Staining was scored in skeletal, visceral and heart muscles such that (111) denotes strong staining in all muscle lineages and (2) denotes no antibody staining in all lineages. All 5 0 constructs maintained the same strong level of reporter activity indicating that sequences required for Act57B expression at high levels are contained within the 2593/12 bp fragment. Clearly, all of the sequences controlling stage and tissue specific expression of Act57B are contained within this short 595 bp promoter element. To aid us in identifying important regulatory sequences within the 2593/12 region we sequenced the upstream region of ActC2, the D. virilis homologue of Act57B (Loukas and Kafatos, 1986; Lovato et al., 2001 ). Fig. 4 shows the sequence alignment for the promoter regions of Act57B and ActC2. Close to the coding sequence of each gene, there are two regions of strong similarity. One of these is the location of the transcription start site identified above and the other is the TATA box region.
The strong conservation suggests that they are important to the expression of Act57B.
Distal to the TATA box, there are additional sequence similarities at: 289/280, 2106/2101, 2131/2120, 2150/ 2144/, 2169/2161, 2277/2197, 2348/2309, 2424/ 2397, and 2463/2454. In Fig. 4B , the two largest blocks of sequence similarity are highlighted. The first of these large blocks, Region a, at 2277/2197 is 31 bp in length and differs between the two species at only a single nucleotide. A more distal sequence, designated Region b, at 2424/2397 is 27 bp in length and also differs between the two species by a single nucleotide. That these elements have been conserved over 60 million years suggests strongly that they perform important regulatory roles in Act57B transcription. We performed a database search with the conserved sequences to identify potential regulatory factor binding sites (http://genomatix.gsf.de/cgi-bin/matinspector/matinspector.pl). Within Region a there is a consensus MEF2 binding site (Fig. 4B ). The next closest sequence to a consensus MEF2 binding site contains two mismatch nucleotides and was not conserved in D. virilis. Region b, as well as other conserved sequence, contained no known muscle-specific transcription factor binding sites.
Requirement of conserved sequences
To determine the functional importance of conserved regulatory sequences within the 2593/12 fragment we generated an additional 5 0 deletion construct (2278/12) deleting Region b, and a second construct containing Region b, but not Region a (2593/2245). These constructs were then assayed for their ability to direct lacZ reporter activity in transgenic flies. As shown in Fig. 5 , lacZ expression in the 2277/12 transgenic lines was decreased in visceral ( Fig. 5B ) and skeletal ( Fig. 5F ) lineages, and cardiac expression was also detected although strongly reduced ( Fig. 5J ) compared to the 2593/12 construct. Reporter constructs consisting of the upstream fragment containing Region b were unable to confer muscle-specific lacZ expression in any of the muscle lineages ( Fig. 5C ,G,K). These results suggest that Region b may regulate Act57B expression levels while Region a specifies expression in muscle tissue, possibly via MEF2 activity. To further address this we fused the upstream region, containing Region b, back with the downstream sequence containing a mutated MEF2 site in Region a. While mutating the MEF2 site reduced reporter activity, we were able to recover the muscle specific reporter expression patterning in skeletal and visceral muscle although cardiac muscle failed to stain (Fig.  5D ,H,L). These results suggested a regulatory role in muscle development for both MEF2 and additional transcription factors binding in Region b and Region a. Furthermore, although expression in cardiac tissue was generally more sensitive to deletion or mutation of these promoter sequences, our results in general show similar sequence requirements for all three lineages. To confirm that the 2278/12 or 2593/12 mutant MEF2 constructs show significantly less activity than the 2593/12 minimal construct, we performed quantitative b-galactosidase assays of embryos homozygous for the lacZ reporter constructs 2593/12, 2278/12, and 2593/12 mutant MEF2. We assayed three independent lines for each of the constructs using 10 mg of total embryo protein; the mean bgalactosidase activity for each construct is shown in Table 1 . Using Student's t-test (Gardiner, 1997) we found that bgalactosidase activity of lines carrying the 2278/12 or the mMEF2 constructs were significantly (P , 0:05) reduced compared to the full-length 2593/12 element. Furthermore, the level for the minimal construct 2593/12 was greater than the sum of b-galactosidase levels for . Promoter-lacZ reporter constructs consisting of this upstream 2593 to 2278 sequence were unable to confer any muscle-specific reporter expression (C,G,K). Fusing the 2593 to 2278 sequence with the downstream region where the MEF2 site is mutated (mMEF2) recovered muscle-specific lacZ expression, however reporter activity was diminished demonstrating the importance of this single MEF2 site in Act57B expression (D,H,L). In (L), the irregular reporter expression in cells surrounding the heart was not consistently observed in other lines bearing this construct and likely represent a mild enhancer-trap phenotype. Scale bars represent 100mm.
constructs 2278/12 and 2593/12 mutant MEF2. This suggests that factors bound at the MEF2 site act synergistically with factors bound at the upstream region to activate Act57B transcription.
Requirement of MEF2 for Act57B expression
The results described above demonstrate that a consensus MEF2 binding site is required for normal activity of the 2593/12 fragment. To determine if MEF2 plays a direct regulatory role in Act57B expression we first sought to determine if MEF2 binds to the consensus sequence of the promoter (Fig. 6A) . In electrophoretic mobility shift assay (EMSA), in vitro translated MEF2 protein bound to a double stranded oligonucleotide containing the putative MEF2 binding site within the 2593/12 element (Fig. 6A , lane 2). MEF2 binding was specific since an unlabeled wild type oligonuculeotide competed strongly for MEF2 binding (Fig. 6A, lanes 3-4) and a mutant oligonucleotide was unable to compete (Fig. 6A, lanes 5-6) . Note that the mutant sequence within this experiment contained the same mutation tested in transgenic flies (Fig. 5) .
To determine if MEF2 was present in nuclei of embryos and capable of binding to the Act57B promoter MEF2 binding site we performed an EMSA using embryonic nuclear extract (Fig. 6B) . The MEF2 consensus sequence was bound specifically by nuclear protein (Fig. 6B, lanes 2-6) . To demonstrate the protein bound was in fact MEF2, an anti-MEF2 antibody (Lilly et al., 1995) blocked formation of the oligonucleotide/protein complex (Fig. 6B, lanes 7-8) . These results indicate that MEF2 was present in the embryonic nuclear extract and was able to bind to the consensus sequence in the Act57B promoter. In addition to the MEF2/ probe interaction, we saw binding activity with a faster electrophoretic mobility. This interaction was non-specific as shown by equal competition with wild type (lanes 3-4) and mutant (lanes 5-6) unlabeled oligonucleotides.
Knowing that MEF2 bound the consensus sequence of Act57B promoter we sought to address the regulatory role of MEF2 in vivo using in situ hybridization on Mef2 mutant (Mef2 P544 /Mef2 P544 ) embryos (Fig. 7) . Comparing the Act57B expression patterns in wild type (Fig. 7A-C) and Mef2 mutants (Fig. 7D-F) emphasized the importance of MEF2 regulation in embryogenesis. There was a reduction in Act57B expression at stage 10 in the mutants (compare Fig. 7A and Fig. 7D ) with a small amount of discontinuous staining in the visceral myoblasts. By stage 13, Act57B expression was severely reduced in the skeletal myoblasts of Mef2 mutants (compare Fig. 7B and Fig. 7E ) and at stage 16 there was no staining in cardiac muscle of in situ hybridized Mef2 P544 /Mef2 P544 mutant embryos (compare Fig. 7C  and Fig. 7F) . Ranganayakulu et al. (1995) and Bour et al. (1995) both documented cell death in the somatic muscle lineage at later stages of development in Mef2 mutants, stage 16 and stage 15 respectively. However, Lilly et al. (1995) using nautilus, apterous, and S59 probes, and Bour et al. (1995) using a b3-tubulin probe, demonstrated that skeletal myoblasts are present in normal numbers as late as stage 14. Therefore, the observed reduction in Act57B transcription levels in skeletal myoblasts at stage 13 (Fig.  7B,E) is not artefactually reduced due to death of myoblasts, but a result from an absence of MEF2 transcription factor to maintain high levels of Act57B expression.
By generating a line of flies mutant for Mef2 (Mef2 P544 / Mef2 P544 ) and carrying the 21742/12-lacZ construct we were also able to demonstrate a requirement for MEF2 in controlling the expression of the Act57B promoter-lacZ construct. b-galactosidase expression in the Mef2 mutants In vitro translated MEF2 protein bound to the MEF2 site (complex b), is competed with a wild type MEF2 oligonucleotide sequence (wtMEF2), and is competed only weakly by a mutant MEF2 oligonucleotide sequence (mMEF2), demonstrating specificity for MEF2 binding within the context of the Act57B promoter. (B) Gel mobility shift using nuclear extracts collected from embryos aged 12-20 h. In the absence of competitor, a complex with three closely spaced bands of different MEF2 isoforms is observed (b), wild type MEF2 oligonucleotide (wtMEF2) competes and mutant MEF2 oligonucleotide (mMEF2) does not compete. Addition of MEF2 antibody (aMEF2) diminished the intensity of the multi-band bound complex and much of the signal was restricted to the wells (not shown). Inhibition of complex formation by a MEF2 antibody demonstrates the presence of MEF2 protein in the nuclear extract that specifically bound to the consensus sequence. The additional band seen with high antibody concentration is likely the result of a non-specific interaction (b, bound probe complex consisting of three bands and f, free probe). Competitors were at 50 £ and 300 £ of the labeled oligonucleotide. was strongly reduced compared to 21742/12-lacZ in a heterozygous background at all stages and in all muscle lineages (compare Fig. 7G-I and Fig. 7J-L) . Taken together, these results provide strong evidence that MEF2 is essential for regulation of Actin 57B expression in all muscle lineages during embryogenesis. It is worth noting that the effects of mutating the MEF2 binding site within the promoter fragment (Fig. 5D ) reduced reporter gene expression, however the expression of a wildtype promoter construct in a Mef2 mutant background (Fig.  7J ) was much more seriously reduced. Since there are no additional MEF2 binding sites in the minimal promoter fragment, the residual expression in Fig. 5D may be attributed to recruitment of MEF2 to the promoter by an additional cofactor in the absence of direct MEF2 binding. Furthermore, if additional cofactors are themselves regulated by MEF2, in the Mef2 mutant background expression of these cofactors would be reduced, in turn further reducing Act57B reporter activity. This conclusion is supported by our findings that sequences in addition to the MEF2 site are important to Act57B transcription.
Discussion
Muscle differentiation occurs through the regulated synthesis of structural proteins that carry out diverse processes such as myofibril assembly and function, myoblast fusion, muscle patterning, and interaction with non-muscle components such as nerve and tendon cells. In order to fully comprehend the events that occur during this time, a detailed knowledge of the transcriptional regulatory molecules that control the expression of these structural genes is needed.
In this manuscript we have begun to dissect the regulatory mechanisms controlling expression of a myofibrillar actin gene, Act57B. Actin is one of the earliest structural genes expressed in the developing musculature (Fernandes et al., 1991) , therefore regulators of actin expression also probably regulate some of the key morphogenetic processes that occur early in myogenesis. Act57B is the predominant actin gene expressed in all muscle lineages in the embryo, and is also expressed at larval and adult stages (Fyrberg et al., 1983; Tobin et al., 1990) . Through deletion analysis, we have identified a single 595 bp element that completely recapitulates the embryonic expression pattern. The transcriptional regulator MEF2 is expressed in a manner that precedes and parallels that of Act57B (Bour et al., 1995; Lilly et al., 1995) , suggesting a role for MEF2 in regulation of this actin gene. Contained within the 595 bp regulatory element is a consensus MEF2 binding site, which we have shown specifically binds MEF2 using gel shift assays. Mutation of this site in lacZ-reporter constructs severely diminishes reporter activity. In addition, we observed a severe reduction in the endogenous Act57B expression in the Mef2 mutant background.
Taken together these findings demonstrate that MEF2 is a direct and essential transcriptional regulator of Act57B expression during embryogenesis. MEF2 functions over a broad developmental time starting at stage 10 in the visceral muscle precursors and in all muscles by the end of embryogenesis. Taylor (2000) described a putative nuclear protein, Dmeso18E, whose expression in visceral and somatic myoblasts is dependent upon MEF2 function at stage 11-12. Along with a reduction in Dmeso18E expression, disruption of Act57B expression represents the earliest phenotype observed to date in Mef2 mutants.
A number of MEF2 targets have been previously characterized, both in Drosophila and vertebrate systems (reviewed in . These include the Drosophila tropomyosin (TmI) gene, where expression in skeletal and visceral muscle cells, but not the heart, is dependent upon MEF2 (Lin et al., 1996) . Paramyosin gene expression in skeletal and visceral muscle depends critically upon a conserved MEF2 site (Arredondo et al., 2001) . Also, MEF2 regulates Drosophila b3 tubulin (bTub60D) and a PS2 integrin expression through enhancers specific to early somatic and visceral muscle respectively Damm et al., 1998) . Similar modular regulation is observed in vertebrate muscle protein genes.
An underlying feature of these genes is that the enhancers that have been characterized control a subset of the whole expression pattern of the gene in question. Our characterization of Act57B regulation contrasts with these results by demonstrating that MEF2 is required for high levels of expression of Act57B in all muscle lineages, and furthermore that MEF2 controls this expression in all lineages via a single site. To our knowledge, this is the only example of MEF2 directing expression of a structural gene in all muscle types through a single binding site. Furthermore, our deletion analyses did not identify any sequence elements in this gene which contribute to expression in specific lineages since the isolated a 595 bp element contains all of the regulatory sequences required for Act57B expression in skeletal, visceral, and cardiac muscle lineages. Mutation or deletion of this 595 bp element results in general effects upon expression in all lineages.
The results presented in this manuscript also indicate that MEF2 function alone is not sufficient to induce Act57B expression at high levels in muscle cells. LacZ reporter constructs with the MEF2 site and flanking sequences, but lacking region b (construct 2278/12), had reduced reporter activity. In addition, ectopic expression of Mef2 under control of a heat shock promoter did not induce expression of Act57B (unpublished observations). This is consistent with the findings of Lin et al. (1996) where the TmI MEF2 site alone was unable to direct expression of a lacZ reporter.
We also show that low levels of Act57B expression occur in the absence of MEF2 function, either when the MEF2 site is mutated in the minimal reporter construct (construct 2593/12 mMEF2) or in a Mef2 mutant background. The simplest explanation for these results is that MEF2 functions with additional factor(s) to regulate muscle gene expression and that the presumptive cofactor is also restricted in its activity to the musculature.
However, the identity of this putative cofactor is far from clear. PDP1 has been shown to be a MEF2 cofactor in Drosophila, regulating TmI gene expression in the somatic mesoderm (Lin et al., 1997b) , however there are no PDP1 binding sites contained within the minimal Act57B enhancer fragment. In vertebrate systems the myogenic bHLHs (MyoD, myogenin, Myf5, MRF4) have been shown to regulate gene expression with MEF2 through E-boxes (reviewed in Molkentin and Olson, 1996) . Again, there are no E-boxes contained within the minimal Act57B enhancer. Since the upstream region required for high promoter activity contains areas of strong sequence conservation between D. melanogaster and D. virilis, it is likely that these might represent binding sites for the putative cofactors. It is unclear at this time exactly what factors may bind to this region.
All of the data presented in this paper indicate that the Act57B locus is under the positive control of MEF2 and potential cofactors. Moreover, none of our deletion constructs show inappropriate expression, suggesting the absence of cis-acting negative regulatory sequence within the enhancer. However, there is a time during early embryogenesis when MEF2 is present, but Act57B is not expressed. This could simply be due to the absence of positively acting cofactors at this stage in development. Alternatively, this could be the result of negative regulators interacting directly with factors bound to the Act57B promoter. Histone deacetylases have been shown to interact directly with MEF2 (Miska et al., 1999; Lemercier et al., 2000; Lu et al., 2000a) and this interaction has a potentially important role in regulating vertebrate myogenesis (Lu et al., 2000b; McKinsey et al., 2000) . Although the Drosophila genome sequence (Adams et al., 2000) has revealed several potential open reading frames for histone deacetylases, it is not known if these are expressed or functional in the developing Drosophila mesoderm. Future analysis of muscle specific structural genes will help illuminate the network of positive and negative regulatory factors which contribute to the development of multiple physiologically distinct muscle lineages.
Experimental procedures
Drosophila strains and culture
Drosophila stocks were raised at 258C on Drosophila Jazz Food Mix (Applied Scientific Inc., South San Francisco, CA) in plastic vials or half pint bottles.
To study Act57B expression patterning in Mef2 mutants, we used in situ hybridization of Mef2 P544 embryos (Lilly et al., 1995) . The Mef2 P544 allele was maintained over an SM6b balancer chromosome which contains an eve-lacZ reporter. Homozygous Mef2 mutants were identified based on the absence of lacZ staining using a lacZ antisense probe (see in situ hybridization below), or by the abnormal gut phenotype of Mef2 null individuals at stage 16 (Bour et al., 1995; Lilly et al., 1995) .
To study Act57B-lacZ reporter activity in a Mef2 mutant background, flies from the 21742/12 promoter-lacZ construct linked to the third chromosome were crossed into an SM6b/Mef2 P544 background using standard genetic crosses. This generated yw; SM6b,eve-lacZ/Mef2 P544 ; P[w 1 Act57B-lacZ]C6-25 which was stained with anti-b-galactosidase antibody both to distinguish the mutant and nonmutant offspring as well as to assay the activity of the Act57B-lacZ reporter.
In situ hybridization
A pBR322 plasmid containing Act57B was obtained from Dr Sarah Tobin (Stanford University, CA) and the entire Act57B gene is contained with a single 5.4 kb EcoRI fragment of this plasmid. This fragment was subcloned into pBluescript KS II (Stratagene, La Jolla, CA) and clones in each orientation were isolated: E119-5 has the 3 0 end of the gene closest to the M13 reverse sequencing primer, and E119-22 has the 5 0 end of the gene closest to the M13 reverse sequencing primer. To generate a piece of the 3 0 UTR sequence for use as an in situ hybridization probe, a PCR was performed upon E119-5 using a 1 strand primer immediately 5 0 to the translation stop site (Act57B 3 0 1 : 5 0 -ATCGTCCACCGCAAGTGC-3 0 ), and M13 reverse sequencing primer. This generated a 1.4 kb product which was ligated into pGEM-T Easy (Promega Corp., Madison, WI) and clones with inserts in each orientation were isolated (E125-1 and E125-2). For antisense probe generation, E125-1 was linearized with AccI and probe was generated with T7 RNA polymerase (Roche Molecular Biologicals, Indianapolis, IN). For sense probe generation, E125-2 was linearized with HindIII and probe was generated with T7 RNA polymerase. Digoxigenin-labeled probes were applied to embryos aged 0-16 h according to O'Neill and Bier (1994) . Following hybridization, signal was detected using Alkaline Phospatase BCIP/NBT substrate (Vector Laboratories, Burlingame, CA). Stained embryos were cleared and mounted in 80% (v/v) glycerol for photography. In order to assay the expression of Act57B in the Mef2 mutants (Mef2 P544 /Mef2 P544 ) we hybridized the embryos with the Act57B and a lacZ antisense probes. The lacZ probe was generated by linearizing the E72-1 plasmid (pBluescriptSK plasmid containing lacZ) with NdeI and probe synthesis with T7 RNA polymerase was as described above. MEF2 mutants were identified either by the lack of the eve-lacZ expression from the SM6b balancer, or by the gut morphology of stage 16 embryos.
Primer extension assay
Total RNA was extracted from wild type embryos aged 0-2 h (control) and 15-17 h at 258C using TRI reagent according to the manufacturer's instructions (Molecular Research Center Inc., Cincinnati, OH). A primer extension oligonucleotide (5 0 -ATCGTCACACATTTTGTTTTAG-3 0 )
was synthesized that was complementary to the Act57B coding sequence. Total RNA (10-60 mg) and primer (100 pg) were coprecipitated and resuspended in TE (8 ml). To the samples 5 £ PE buffer (2 ml) (Carey and Smale, 2000) was added. The primer was annealed for 3 min in a 758C water bath which was then allowed to cool slowly to 358C. The dNTPs (1ml each of 5 mM dGTP, dATP, dTTP, and 2.5 ml 50 mM 32 P dCTP), PowerScript reverse transcriptase (0.5 ml) (Clontech, PaloAlto, CA) and buffer (34 ml) (Carey and Smale, 2000) were added to the reaction. The reactions were then incubated for 1 h at 378C. After precipitation, the products of the primer extension were resuspended in Sequenase stop solution (4 ml) (USB Corp., Cleveland, OH). DNA sequencing reactions were performed using the same oligonucleotide primer and the T7 Sequenase version 2.0 DNA sequencing kit (USB Corp., Cleveland, OH). Primer extension and sequencing reaction products were separated on a denaturing polyacrylamide gel (Sambrook et al., 1989) . After electrophoresis at 2000 V/40 mA the gel was fixed, dried for 1 h, and exposed to film overnight.
Generation of promoter-lacZ constructs
Genomic fragments for fusion to lacZ reporter constructs were generate by PCR. The 1100/1831 intron construct was generated using 57B Ex1 1 (5 0 -ATGAAGTTGCT-GCTCTGG-3 0 ) and 57B E £ 2-(5 0 -ACCGGCCTTGCA-CATGCCGGAGC-3 0 ). The largest 22479/12 construct was generated using M13 reverse primer and 57B Ex1-PCR (5 0 -CTAAAGTATCGCCGCGTTGGT-3 0 ) using E119-22 as a template. Each of these products were ligated into pGEM-T Easy, and transferred from there to the Pelement vector CaSpeR-hs-AUG-bGal (CHAB; Thummel and Pirrotta, 1992) using appropriate flanking restriction sites. The 5 0 deletion constructs were generated using the following primers. 21742/12: 57B 5 0 1 II (5 0 - EcoRI site which was used for the subsequent cloning step. These products were ligated into pGEM-T Easy and subsequently directionally cloned into CHAB using the engineered EcoRI and XhoI sites. Note that all of the constructs tested were cloned into CHAB although all upstream constructs contained the endogenous Act57B transcription start site we supplied each with an heterologous hsp70 promoter in case the small amount of 5 0 leader from Act57B was poorly functional or non-functional. Mutation of the MEF2 site was carried out by PCR-site directed mutagenesis (Horton, 1993) . Oligonucleotides with the MEF2 site mutated to a NotI site were used to generate primary products from a genomic DNA template: 57B 5 0 1V and 57B mm-(5 0 -CCGATCCGCCGCGGCCCCGAT-CCTTCAGCATAGG-3 0 ); 57B Ex1-PCR II and 57B mm 1 (5 0 -CTGAAGGATCGCGGCCGCGGCGGATCG-GCCGGTGG-3 0 ) (italicized sequence represents the engineered NotI site). Primary PCR products were gel purified and used as templates in a secondary PCR to generate the final Act57B enhancer with the MEF2 site mutated. This was ligated into pGEM-T Easy and subcloned into CHAB as described above. The presence of the mutation was confirmed both by NotI digestion and sequencing. CHAB constructs were injected into D. melanogaster embryos following Bernstein and Cripps (2000) ; three to five independent homozygous transgenic lines were generated for each construct.
GGGAATTCTACTTAAATGTATTTTCCGG-3
Immunohistochemistry
Embryos were collected on agar/grape juice plates for 16 h at 258C. Immunohistochemistry of whole-mount embryos was performed as described in Patel et al. (1987) for three to five independent lines for each construct. The primary antibody was an anti-b-galactosidase monoclonal antibody (1:400, Promega Life Science, Madison, WI) and localization was detected using Vectastain Elite Staining Kit (Vector Laboratories, Burlingame, CA). Embryos depicting average b-galactosidase expression for each of the enhancer-lacZ constructs were cleared either in 80% (v/v) glycerol or in methyl salicylate (Patel, 1994) and mounted for photography.
To depict accurately the differences in lacZ reporter construct expression in Fig. 5 , equivalent numbers of embryos homozygous for each lacZ reporter construct were processed in parallel with identical antibody incubation and staining reaction times. Photo documentation of these embryos was performed using the same film exposure times and any electronic brightness/contrast manipulations were done on these embryo photos en masse.
Sequence analysis of D. virilis ActC2 upstream sequence
The isolation of a pBluescript plasmid containing ActC2 was described elsewhere (Lovato et al., 2001) . To determine the sequence upstream of the translation start site, this plasmid was first sequenced using 5 0 -TCCGTTTCTCTATCCG-3 0 which annealed in exon 1 at 1213 bp. Subsequent primers were generated from the obtained sequence. This process was repeated until we had upstream sequence to 2950 bp from the transcription start site. To identify sequences similar between D. melanogaster and D. virilis, sequence comparisons were performed using the lalign program (http:// www.ch.embnet.org/software/LALIGN_form.html).
b -Galactosidase assay
To directly compare b-galactosidase levels in transgenic lines carrying our promoter-lacZ constructs, embryos were collected from homozygous transgenic lines for 2 h on agar/ grape juice plates and aged for 14 h at 258C. Soluble proteins were extracted from approximately 100 embryos by homogenization in assay buffer (Ashburner, 1989) , and the suspension was spun briefly to clarify it. To control for variation in protein extraction, protein yield was quantified using Bradford reagent (5 ml extract, 70 ml water, 925 ml Bradford reagent) (Bradford, 1976) . We used b-galactosidase standards at 0.1 ng/ml, 0.5 ng/ml, 1 ng/ml, and 5 ng/ml, to determine absolute soluble protein concentrations. Identical amounts of total embryo protein for each line (10 mg) homogenization buffer (for a final volume of 1 ml) and b-dgalactopyranoside (10 ml of a 100 mM stock) were mixed and incubated at 378C. Optical density readings were taken at 0.5, 1, and 2 h at 574 nm.
Nuclear extract preparation and electrophoretic mobility shift assay
For nuclear extracts, embryos were collected for 8 h and aged 12 h on agar/grape juice plates at 258C. 500 mg of embryos of ages 12-20 h were recovered and subsequently subject to the nuclear extraction protocol of Lichter and Storti (1991) . This yielded 0.1 mg of extract.
For electrophoretic mobility shifts, the probe and unlabeled wild type competitor were 5 0 -AAGGATCTATTTT-TAGGCGGAT-3 0 , with GG overhangs on the 5 0 ends. The wild type probe was labeled by filling in the G overhangs with 32 P dCTP using Klenow enzyme (Roche Molecular Biochemicals, Indianapolis, IN) and diluted to 50,000 cpm/ml. The mutant competitor was 5 0 -AAGGATCGC-GGCCGCGGCGGAT-3 0 , again with 5 0 GG overhangs.
Wild type and mutant competitors were diluted to 50 £ and 300 £ concentrations of the 50,000 cpm probe. MEF2 lysate was generated using the plasmid pCDNA-DMEF2 provided by Dr Brian Black (University of California, San Francisco, CA) and Promega TNT kit (Promega, Corp., Madison, WI) following the manufacturer's protocol. Binding reactions consisted of polydI.dC (1 mg for reactions containing the in vitro MEF2 translated protein and 2 mg for reactions containing the nuclear extract), 5 £ buffer (2 ml), MEF2 lysate (3 ml) or nuclear extract (1 ml of 2 mg/ml stock), and water to bring the final volume to 10 ml. Nonspecific binding was allowed to proceed for 15 min on ice. Labeled probe and competitors were then added and incubated 15 min at room temperature. Entire reactions were loaded onto a 3% non-denaturing polyacrylamide gel which was run at 20-25 mA at 48C. The gel was then dried for 1 h and exposed to film overnight.
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